Share This Page
M-M-R II Drug Profile
✉ Email this page to a colleague
Summary for Tradename: M-M-R II
| High Confidence Patents: | 0 |
| Applicants: | 1 |
| BLAs: | 1 |
Pharmacology for M-M-R II
| Physiological Effect | Actively Acquired Immunity |
| Established Pharmacologic Class | Live Attenuated Measles Virus Vaccine Live Attenuated Mumps Virus Vaccine Live Attenuated Rubella Virus Vaccine |
| Chemical Structure | Measles Vaccine Mumps Vaccine Rubella Vaccine Vaccines, Attenuated |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for M-M-R II Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for M-M-R II Derived from DrugPatentWatch Analysis and Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for M-M-R II Derived from Patent Text Search
No patents found based on company disclosures
M-M-R II Market Dynamics, Financial Trajectory, Patent Exclusivity, and Competitive Risk
M-M-R II is Merck’s live attenuated measles, mumps, and rubella vaccine. Its commercial profile is mature, stable, and largely protected by manufacturing complexity, regulatory requirements, public procurement, and Merck’s established distribution network rather than by active product patents. Merck does not separately disclose M-M-R II revenue. The product is reported within a combined franchise that includes ProQuad and Varivax, limiting product-level financial analysis.[1]
The main commercial risks are gradual share loss to GSK’s Priorix, procurement price pressure, changes in national immunization policy, and manufacturing interruptions. Paragraph IV litigation and conventional generic substitution are not the primary risks because M-M-R II is licensed as a biologic vaccine rather than an FDA small-molecule drug.
What is M-M-R II and how is it used?
M-M-R II is a lyophilized, live attenuated vaccine indicated for active immunization against measles, mumps, and rubella. It is administered by subcutaneous or intramuscular injection after reconstitution.[2]
The product is used primarily in:
- Routine pediatric immunization.
- Catch-up vaccination for unvaccinated children and adults.
- Outbreak control.
- Pre-travel vaccination.
- Healthcare workers and other high-risk groups.
- School and institutional vaccination programs.
The standard U.S. childhood schedule calls for the first dose at 12 to 15 months and the second dose at 4 to 6 years. During outbreaks or for international travel, the second dose may be administered earlier under CDC guidance.[3]
M-M-R II product profile
| Attribute | M-M-R II |
|---|---|
| Active components | Live attenuated measles, mumps, and rubella viruses |
| Sponsor | Merck & Co., Inc. |
| FDA pathway | Biologics license application |
| Dosage form | Lyophilized powder for injection |
| Administration | Subcutaneous or intramuscular |
| Primary market | Pediatric and public-health immunization |
| U.S. approval history | Original U.S. licensure dates to 1978 |
| Preservative status | Preservative-free |
| Key excipients | Includes gelatin and trace neomycin |
| Therapeutic category | Preventive vaccine |
| Direct U.S. competitor | GSK Priorix |
M-M-R II is not a treatment for active measles, mumps, or rubella infection. Demand is driven by immunization schedules and public-health policy rather than disease-treatment volume.
How large is the M-M-R II market?
The global market is part of the broader measles, mumps, and rubella vaccine segment. Public financial data do not provide a reliable standalone revenue figure for M-M-R II.
Merck groups M-M-R II with ProQuad and Varivax in its vaccine sales disclosures. That combined group includes both the trivalent MMR product and varicella-containing products, so it cannot be used as a direct M-M-R II revenue proxy.[1]
Revenue disclosure and financial visibility
Merck’s vaccine portfolio is economically significant, but the company’s largest disclosed vaccine product is Gardasil/Gardasil 9. M-M-R II is included in a smaller, mature franchise whose financial contribution is not separately reported.
| Financial question | Public answer |
|---|---|
| Is M-M-R II revenue separately disclosed? | No |
| Is M-M-R II reported with other vaccines? | Yes |
| Can Merck’s combined ProQuad/M-M-R II/Varivax sales be attributed to M-M-R II? | No |
| Does Merck identify M-M-R II gross margin? | No |
| Does Merck disclose M-M-R II unit volume? | No |
| Is there a standalone M-M-R II forecast from Merck? | No |
The product’s financial trajectory is therefore best assessed through market structure, vaccination volumes, price, procurement access, and competitive entry.
What is driving M-M-R II market demand?
Demand has four main drivers.
Routine childhood immunization
The largest demand source is the established two-dose pediatric schedule. The U.S. birth cohort creates a recurring base of approximately 4 million children annually, although actual doses vary with vaccination coverage, timing, wastage, catch-up vaccination, and public-health campaigns.
Outbreak response
Measles outbreaks increase short-term demand for MMR vaccines. Outbreak-related vaccination can shift the timing of doses and create localized spikes in orders, but it does not necessarily produce sustained long-term volume growth.
Government procurement
Public-sector purchasing is important. Vaccines are distributed through federal, state, local, school, military, and institutional channels. Government tenders and negotiated contracts can constrain net pricing even when underlying clinical demand is stable.
Coverage recovery
Pandemic-related disruptions reduced routine childhood vaccination in many markets. Recovery in pediatric vaccination coverage supports demand, while persistent under-vaccination creates both public-health risk and catch-up opportunity.[4]
How does M-M-R II compare with Priorix?
GSK’s Priorix is the principal direct U.S. competitor. The FDA approved Priorix in June 2022 for active immunization against measles, mumps, and rubella in individuals 12 months of age and older.[5]
| Factor | M-M-R II | Priorix |
|---|---|---|
| Sponsor | Merck | GSK |
| Vaccine type | Live attenuated MMR | Live attenuated MMR |
| U.S. FDA approval | Long-established product | Approved 2022 |
| Market position | Incumbent | Newer entrant |
| Pediatric use | Yes | Yes |
| Public procurement access | Established | Expanding |
| Substitution pathway | Product-specific biologic procurement | Product-specific biologic procurement |
| Biosimilar status | None | None |
| Main commercial advantage | Supply history and installed distribution | Competitive alternative and supply diversification |
Priorix does not operate as an automatic generic substitute for M-M-R II. Vaccines are selected through formularies, contracts, public programs, and clinical procurement systems. A new supplier can gain share through price, supply reliability, contracting, and regional availability without triggering an ANDA-style substitution process.
GSK’s entry increases pricing pressure over time. It also gives governments and health systems a second major supplier, reducing dependence on Merck.
What patents protect M-M-R II?
M-M-R II’s current commercial protection is not primarily patent-based. The product has been marketed for decades, and any foundational composition, strain, formulation, or manufacturing patents associated with the original product would generally be expected to have expired.
No current Orange Book patent estate is the central barrier to competition for M-M-R II.
Patent and regulatory protection
| Protection category | M-M-R II position |
|---|---|
| Foundational product patents | Expected to be expired |
| Current formulation patent moat | No material public evidence of a blocking estate |
| Manufacturing know-how | Important and difficult to replicate |
| FDA biologics license | Active regulatory authorization |
| New biologic exclusivity | Not a current commercial barrier for this legacy product |
| Orange Book listing | Not the principal patent record for the product |
| Purple Book biosimilar competition | No approved biosimilar |
| Paragraph IV exposure | Not applicable in the conventional ANDA sense |
M-M-R II was approved before the modern biosimilar framework. The 12-year reference-product exclusivity period created by the Biologics Price Competition and Innovation Act does not function as a new protection period for a product first licensed in 1978.[6]
When does M-M-R II lose exclusivity?
M-M-R II has already lost effective patent exclusivity. Its commercial position depends on regulatory authorization, manufacturing capability, product quality, and procurement relationships.
The relevant timeline is:
| Date or period | Event |
|---|---|
| 1978 | M-M-R vaccine products received U.S. licensure |
| 1980s-2000s | Product and manufacturing patents, where applicable, matured or expired |
| 2010s | M-M-R II remained an established incumbent in pediatric vaccination |
| 2022 | FDA approved GSK’s Priorix in the United States |
| 2024 onward | Competition is primarily commercial and supply-based rather than patent-based |
There is no single future “loss of exclusivity” date comparable to a branded small-molecule drug. The commercial franchise is already post-patent, while ongoing market access depends on maintaining the BLA, manufacturing controls, pharmacovigilance, and supply continuity.
Are there Paragraph IV challenges to M-M-R II?
No conventional Paragraph IV challenge is expected for M-M-R II.
Paragraph IV certifications arise under the Hatch-Waxman framework for ANDAs referencing drugs approved under the Federal Food, Drug, and Cosmetic Act. M-M-R II is licensed as a biologic vaccine under the Public Health Service Act. A competing vaccine would generally need its own biologics license or pursue an applicable biologic pathway rather than file a standard ANDA asserting invalidity or non-infringement of Orange Book patents.[6]
Generic launch risk
The practical launch scenarios are:
- A separately developed MMR vaccine obtains its own FDA license.
- A competing biologic vaccine gains market access through public contracts.
- A foreign manufacturer expands into the U.S. market.
- An alternative combination vaccine, such as MMRV, captures part of the demand.
- A supply shortage shifts orders between approved manufacturers.
The first scenario has already occurred through Priorix. The competitive impact is gradual share and pricing pressure, not an automatic patent-triggered generic launch.
What formulation and manufacturing barriers protect M-M-R II?
Manufacturing know-how is more important than patent protection.
M-M-R II contains live attenuated viral strains that must be produced, stabilized, lyophilized, tested, and released under stringent biologics controls. Key barriers include:
- Maintenance of qualified viral seed lots.
- Control of attenuation and genetic characteristics.
- Cell-culture and viral propagation processes.
- Lyophilization and reconstitution performance.
- Potency testing for three viral components.
- Stability throughout refrigerated distribution.
- Aseptic filling and packaging.
- Lot-release testing.
- Cold-chain management.
- Regulatory validation of process changes.
These barriers increase development cost and time. They also make supply reliability commercially valuable. A competitor may obtain regulatory approval but still face difficulty achieving scale, yield, consistent potency, and broad government-contract coverage.
The formulation itself is not necessarily a high-value patent moat. Its practical defensibility comes from validated process control and regulatory history.
What is the FDA and Orange Book status of M-M-R II?
M-M-R II is an FDA-licensed biologic vaccine. It is not treated like a conventional small-molecule product with a standard Orange Book exclusivity profile.
The FDA’s biologics framework covers:
- Manufacturing controls.
- Potency and identity testing.
- Sterility and purity.
- Clinical and post-marketing safety.
- Labeling.
- Lot consistency.
- Facility inspection.
- Pharmacovigilance.
The absence of an Orange Book patent barrier does not mean that market entry is simple. A competing MMR vaccine still requires regulatory approval, validated manufacturing, clinical support, and distribution infrastructure.
What patent litigation affects M-M-R II?
Publicly disclosed information does not identify a material active patent dispute centered on M-M-R II. The principal competitive issue is commercial entry by Priorix rather than infringement litigation.
No significant M-M-R II-specific settlement agreement or Paragraph IV patent settlement is publicly associated with the product. Merck’s broader vaccine litigation, product-liability matters, and intellectual-property disputes should not be conflated with M-M-R II-specific market protection.
What licensing deals support M-M-R II?
M-M-R II’s commercial model is primarily based on Merck’s own biologics manufacturing, regulatory ownership, and distribution. No major current licensing transaction appears to determine the product’s U.S. economics.
International supply can involve government procurement, distributors, affiliates, and public-health organizations. Those arrangements affect geographic access and net pricing but are distinct from a patent license.
What geographic markets are most important?
The United States is strategically important because Merck has a long-established pediatric vaccine franchise, public-program access, and a large installed customer base.
Market dynamics differ by region:
| Region | Primary market characteristics |
|---|---|
| United States | Routine pediatric schedule, federal and commercial procurement, Priorix competition |
| Europe | National tenders, country-specific schedules, multiple vaccine suppliers |
| Emerging markets | Price-sensitive tenders, donor programs, coverage expansion |
| Outbreak markets | Temporary demand increases and accelerated campaigns |
| Travel and private markets | Higher flexibility in product selection and timing |
In lower-income countries, procurement price and global supply availability are often more important than brand loyalty. In the U.S. and other high-income markets, quality history, contract access, and supply continuity carry greater weight.
How strong is the M-M-R II commercial franchise?
The patent estate is weak because the product is mature and effectively post-patent. The commercial franchise remains stronger than the patent estate because of operational barriers.
Strengths
- Established FDA license and clinical history.
- Embedded use in routine immunization.
- Merck’s manufacturing scale.
- Broad provider familiarity.
- Existing public and private distribution channels.
- Recurring pediatric demand.
- High consequences of supply interruption, which can favor incumbent suppliers.
Weaknesses
- No meaningful current patent exclusivity.
- Product-specific revenue is not disclosed.
- Priorix provides a direct branded competitor.
- Government tenders can reduce net price.
- Vaccine demand is tied to coverage and policy, not chronic treatment.
- Outbreak-driven volume is irregular.
- Manufacturing problems can cause shortages and reputational damage.
The result is a durable but mature asset. M-M-R II is more likely to experience gradual margin and share pressure than abrupt patent-driven revenue collapse.
What generic and biosimilar launch risks exist?
The biosimilar risk is low in the near term because no FDA-approved biosimilar to M-M-R II is identified. The more relevant risk is a competing live attenuated MMR vaccine licensed through an independent biologics application.
A conventional generic launch is unlikely because:
- The product is a biologic vaccine.
- There is no standard small-molecule ANDA pathway for direct substitution.
- The product contains multiple live viral components.
- Manufacturing equivalence is difficult to demonstrate.
- Public procurement often requires separate qualification.
Priorix already establishes that a competitor can enter without a patent challenge. Future competition is likely to focus on price, tenders, supply reliability, and combination-vaccine positioning.
What is the likely financial trajectory for M-M-R II?
M-M-R II is likely to produce mature, recurring revenue with limited organic growth. The base case is:
- Stable routine demand in developed markets.
- Periodic volume gains from catch-up vaccination and outbreaks.
- Moderate price pressure from Priorix and public tenders.
- Potential share volatility during supply disruptions.
- No patent cliff comparable to a newly launched branded drug.
- Continued contribution to Merck’s broader vaccine portfolio.
Revenue upside could come from improved vaccination coverage, outbreak response, and public-health campaigns. Downside could come from procurement discounts, reduced vaccination rates, manufacturing interruptions, or substitution by competing MMR and MMRV products.
Because Merck does not disclose standalone M-M-R II sales, valuation models should avoid assigning the entire ProQuad/M-M-R II/Varivax revenue line to the product. A defensible model should estimate M-M-R II as a share of the combined franchise and apply mature-vaccine assumptions for volume, price, and gross margin.
Key Takeaways
- M-M-R II is Merck’s established live attenuated measles, mumps, and rubella vaccine.
- Its original U.S. licensure dates to 1978.
- Effective patent exclusivity has expired; manufacturing and regulatory barriers now provide the main protection.
- M-M-R II does not face a conventional Paragraph IV challenge because it is a biologic vaccine rather than a Hatch-Waxman small-molecule product.
- GSK’s Priorix, approved by the FDA in 2022, is the primary direct U.S. competitor.
- Merck does not separately report M-M-R II revenue, unit volume, or margin.
- Financial performance is likely to be stable but mature, with pressure from tenders, competing supply, and procurement pricing.
- No approved biosimilar to M-M-R II is identified.
- The highest-value commercial assets are manufacturing scale, regulatory history, public-contract access, and supply reliability.
FAQs About M-M-R II Market and Patent Risk
Is M-M-R II still patent protected?
M-M-R II does not appear to have a material active patent estate that controls market entry. Its commercial durability comes from biologics manufacturing, FDA compliance, and distribution infrastructure.
Can a generic manufacturer copy M-M-R II?
A conventional generic manufacturer cannot rely on the standard ANDA pathway in the same way as a small-molecule drug. A competing company would generally need to develop and obtain authorization for its own biologic vaccine.
Is Priorix interchangeable with M-M-R II?
Priorix is a competing MMR vaccine, but it is not an automatic generic substitute for M-M-R II. Procurement rules, clinical policy, payer requirements, and provider selection determine substitution.
Does M-M-R II have an Orange Book patent expiration date?
M-M-R II is not principally protected through an Orange Book patent listing. The product’s relevant regulatory status is its biologics license, not a conventional small-molecule Orange Book exclusivity period.
How should investors model M-M-R II revenue?
Investors should model M-M-R II as part of Merck’s mature vaccine portfolio, using vaccination volumes, public procurement pricing, Priorix competition, supply reliability, and catch-up demand. Merck’s combined vaccine revenue disclosures should not be treated as standalone M-M-R II sales.
References
- Merck & Co., Inc. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). M-M-R II prescribing information. Merck Sharp & Dohme LLC.
- Centers for Disease Control and Prevention. (2024). Recommended child and adolescent immunization schedule for ages 18 years or younger, United States.
- World Health Organization. (2023). Measles and rubella surveillance and immunization coverage reports.
- U.S. Food and Drug Administration. (2022, June 3). FDA approves Priorix vaccine for prevention of measles, mumps, and rubella.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
More… ↓
